Used in cancer immunotherapy research, particularly in the development of antibody-drug conjugates (ADCs) targeting tumor-associated antigens. It binds specifically to the 5T4 oncofetal antigen, which is overexpressed in various solid tumors including colorectal, ovarian, and non-small cell lung cancers, making it a valuable tool for targeted therapy development. This antibody serves as a reference in assays to evaluate the binding and functional activity of novel anti-5T4 antibodies. It is also employed in preclinical studies to support the design and optimization of therapeutic antibodies and ADCs by providing a benchmark for efficacy, specificity, and internalization properties.